Top Health Tech Companies in Dublin (91)
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Strong Hiring & Retention: Employee headcount is increasing over the 2023–2026 period, indicating ongoing hiring momentum. Feedback suggests workforce expansion is sustained even if the pace has moderated recently.
Market Expansion: A new Jakarta office was opened in 2026 to deepen engagement across Southeast Asia. Operations span dozens of offices in many countries, supporting customers in more than 80 countries.
Innovation-Driven Growth: New offerings such as the Data Studio AI Assistant and continued development of healthcare interoperability products point to active product investment. Feedback suggests AI and healthcare enhancements are a current strategic focus.
Optum, part of the UnitedHealth Group family of businesses, is a global organization that delivers care, aided by technology to help millions of people live healthier lives. The work you do with our team will directly improve health outcomes by connecting people with the care, pharmacy benefits, data and resources they need to feel their best. Here, you will find...
Optum's Top Stability & Growth Strengths
Profitability: Operating earnings and margins improved notably in 2026, with Q3 operating earnings up sharply year over year and the operating margin rising to 5.6%. Feedback suggests earnings resilience is being supported by operational changes and a shifting business mix.
Strong Revenue Growth: Reported annual revenue expanded from $226.6B in 2023 to $270.6B in 2025, including roughly 12% growth in 2024 and 7% in 2025. This establishes a robust multi‑year revenue trajectory even as recent growth rates have moderated.
Cost & Operational Efficiency: Cost controls and operational improvements are described as lifting earnings despite lower revenue in 2026. Optum Health’s operating earnings rose from $41M to $735M year over year while serving fewer value‑based patients, indicating stronger execution.
Opsona Therapeutics is a leading drug development company specialising in the human immune system. Opsona is identifying new ways to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases. Opsona's drug discovery & development is focused on the role of Toll-Like Receptors (TLRs) and Inflammasome signalling in human immunology. Since 2004, Opsona has also developed a unique and advanced pipeline...
Glanbia Nutritionals is a nutrition solutions partner that helps deliver better nutrition in foods, beverages, and supplements through innovative ingredients and product development support.
Glanbia Nutritionals's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue and volumes are rising across core segments, with ingredient businesses showing solid like-for-like gains and double-digit volume growth in Health & Nutrition year to date 2026. Group revenue also increased and the full-year earnings outlook was raised, signaling accelerating top-line momentum.
Strong Market Position & Advantage: Category leadership in whey protein isolate and custom premix solutions, alongside a major position in American-style cheddar, anchors a defensible competitive position. Scale, manufacturing footprint, and formulation capabilities support this advantage across global food, beverage, and clinical-nutrition customers.
Resilient & Sustainable Growth: Broad-based volume growth across all segments and upgraded earnings guidance point to durable operating momentum. Management’s medium-term targets indicate continued organic expansion in core ingredient businesses.
Webdoctor.ie is Ireland’s award-winning online GP service. As featured in Deloitte’s Fast 50 Technology Awards, Webdoctor.ie is an Irish-owned health technology platform founded and led by healthcare professionals. With 40+ Irish Medical Council registered doctors on its team, Webdoctor.ie can be accessed from anywhere in Ireland with an internet connection on a phone, tablet or computer via the website or...
Thérapie Clinic is a medical-aesthetics provider offering laser hair removal, cosmetic injectables, body treatments, and advanced skin treatments. Founded in Ireland in 2002, it aims to make world-class aesthetic care accessible to everyone and help clients feel more confident in their own skin. Starting with one clinic, it has expanded across Europe and into New York, delivering personalized treatments through...
At Vertigenius™️, we're pioneering the integration of technology and healthcare to address vestibular disorders, improving balance and reducing dizziness. Our innovative approach includes a clinician portal, a patient app, and a wearable head sensor, making rehabilitation accessible and efficient.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for...
Becton Dickinson's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is repeatedly described as a leader across core categories like syringes, prefillable drug-delivery systems, blood collection, and infusion therapy, supported by broad global reach and large installed bases. This entrenched position aids customer stickiness and supports durable demand.
Resilient & Sustainable Growth: A substantial portion of revenue comes from everyday consumables and recurring platforms, which provides steadier sales through cycles. Consistent year-over-year revenue increases and diversified end-market exposure underpin an enduring growth profile.
Future-Ready Strategy: Management is reshaping the portfolio into a pure-play MedTech company and investing in manufacturing capacity and innovation to sharpen focus on higher-value growth areas. Guidance reaffirmations and targeted segment investments indicate disciplined execution toward long-term expansion.
We are the creators of Complete Anatomy, the world’s most advanced 3D anatomy platform. Our revolutionary cloud-based platform allows users to investigate the details of the human anatomy in incredible 3D, transforming medical learning and practice across the world, leading the way in the production of ground-breaking 3D medical technology. Used by over 1,000,000 students, patients and professionals, our software...
MEG is a healthcare digital quality management system, used by healthcare providers in 15+ countries to simplify and streamline time-consuming care quality, patient safety, and accreditation processes across their organisations. Tools for audit, incident, risk, action planning, complaints, feedback surveys and documents and reporting are all conveniently managed on any device from one central location. Save time, gain real-time reporting...
We at SiSú believe in ‘getting the good in’. Our vision is to improve the wellbeing of people everyday by offering our customers naturally great tasting healthy products. A small step in Nurturing a Healthier You. A trusted clean brand known for healthy nourishment and great taste
The Irish Cancer Society is Ireland's national cancer charity, dedicated to supporting patients and their families through free services, advocacy, and funding for ground-breaking cancer research.
Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Viatris's Top Stability & Growth Strengths
Cost & Operational Efficiency: Cost-savings efforts are positioned as a concrete lever to support improved earnings and fund growth priorities, with an enterprise-wide program targeting substantial savings over multiple years. Guidance frames these actions as part of a broader move toward sustained revenue and earnings improvement beginning in 2026.
Resilient & Sustainable Growth: Growth is presented as re-emerging, with management guiding to a return to modest year-over-year revenue expansion in 2026 after a softer 2025. Improving quarterly trends exiting 2025 and a baseline of modest operational growth excluding divestitures support a narrative of stabilization.
Strong Market Position & Advantage: Scale and global reach are repeatedly highlighted as a stabilizing advantage, with broad geographic coverage and a large portfolio supporting access, supply reach, and competitive standing in off-patent medicines. The strategic shift toward complex generics and specialty brands is framed as reinforcing the company’s long-term positioning against pricing pressures.
We are a biotech longevity company on a mission to confront aging and age-related diseases. We’re building a coalition of the best scientists, physicians and investors to develop therapies and products that will help people experience better health for longer in their lives. We are organized to drive scientific innovation with speed and agility to market
Brennan & Co Group is an Ireland-based supplier and service provider of equipment, reagents, consumables, and supply-chain management. Founded in Dublin, the group serves the Life Sciences, Healthcare, Industrial, and Pharmacy sectors across Ireland, Europe, and Asia. It comprises Brennan & Co and three related companies, combining specialized technological products with servicing and supply-chain expertise for customers in technical and...
Sia Partners is a next generation management consulting firm and pioneer of Consulting 4.0. We offer a unique blend of AI and design capabilities, augmenting traditional consulting to deliver superior value to our clients. Counting 1,800 consultants in 18 countries, we expect to achieve USD 300 million in turnover for the current fiscal year. With a global footprint and expertise...
Sia Partners's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Recent investment by Blackstone of up to €250 million in December 2024 provides growth capital and signals external confidence in the firm’s expansion plans. Company statements link this funding to accelerating U.S. growth, M&A, and AI-enabled offerings.
Market Expansion: Multiple acquisitions and a sustained U.S. push (e.g., Notion Consulting, Ready Set Rocket, Precedence, Kaiser Associates) indicate ongoing geographic and service-line expansion across North America and Europe. Leadership attention to the U.S. market and a growing office footprint suggest increased depth in key geographies.
Innovation-Driven Growth: The firm is productizing AI (e.g., SiaGPT and 800+ deployable AI agents by April 2026) and launching new lines like Corporate Strategy, PE & M&A, pointing to growth via differentiated, tech-enabled delivery. Partnerships and ecosystem recognition around NVIDIA and AWS reinforce momentum in AI-driven consulting.
At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Listening for needs and delivering solutions. As a leader in specialty pharmaceuticals, we develop, manufacture, market and distribute innovative treatments for underserved patient populations within neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal...
A public company, founded over 25 years ago, Consensus is the global leader in digital cloud and fax technology. Focusing in the healthcare space, we use interoperability to unify multiple systems that wouldn’t otherwise talk to each other. With exciting new initiatives on the horizon, we are continuing our strategic expansion. Read on to learn why now is the ideal...
Consensus Cloud Solutions's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyst recognition placed the company among the Leaders in worldwide digital fax, supporting a top-tier position in its core niche. Long tenure and scale around the eFax franchise plus regulated-workflow add-ons reinforce defensibility in compliance-heavy document exchange.
Healthy Cash Flow: Free cash flow increased to a record level in 2025, indicating strong cash generation even amid mixed topline performance. Operating cash flow also rose, providing flexibility to fund strategy and capital allocation.
Profitability: Adjusted EBITDA remained very high with margins around the low-50% range, signaling durable profitability. Guidance also points to continued strong earnings power alongside modest revenue growth expectations.
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With 50 years in business, operations in more than 35 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. We are navigating the complexities of healthcare and providing scaled...
Cardinal Health's Top Stability & Growth Strengths
Strong Revenue Growth: Broad-based segment momentum is evident, with Pharmaceutical & Specialty Solutions and the “Other” businesses posting strong year-over-year revenue increases alongside profit expansion. Growth is further supported by increased specialty-pharmaceutical volumes and added distribution capacity for complex therapies.
Profitability: Segment profit and operating earnings are rising faster than revenue in recent periods, indicating improved earnings conversion. Management’s repeated increases to non-GAAP EPS guidance reinforce the view that profitability is strengthening.
Diversified Revenue Streams: Adjacency businesses (at-Home Solutions, Nuclear & Precision Health, OptiFreight) are growing quickly and contributing meaningfully to profit growth. Portfolio expansion through acquisitions is broadening the earnings base beyond core drug distribution.



.jpg)


























